Navigation Links
Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) will host investors and analysts in New York City on November 18, 2010 for an in depth discussion on the current management of Clostridium difficile infection and the market opportunity for fidaxomicin.  A live webcast of the event beginning at 9:00 a.m. ET will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.

The program will feature presentations by:

  • Mark Miller, M.D., Head of Infectious Diseases Division and Chair of Infection Prevention and Control Committee, SMBD Jewish Hospital in Montreal
  • Pedro Lichtinger, President and CEO, Optimer
  • Sherwood Gorbach, M.D., Chief Medical Officer, Optimer and Professor of Public Health & Medicine, Tufts University School of Medicine

  • (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    For additional information regarding this event, please contact Christina Donaghy, Corporate Communications Manager at Optimer Pharmaceuticals, at cdonaghy@optimerpharma.com.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics that has completed two Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/28/2017)... ... Research and Markets has announced the addition of the ... their offering. The global active pharmaceutical ingredients (API) ... by 2025. The rising prevalence of lifestyle-induced & age-related diseases and ... Advancements in recombinant molecular technologies and high capitalization for development of ...
    (Date:2/28/2017)... Feb. 27, 2017  Titan Pharmaceuticals, Inc. (NASDAQ: ... treatment of select chronic diseases utilizing its ProNeura™ ... the U.S. Food & Drug Administration (FDA) has ... Investigational New Drug Application (IND) and has requested ... study pending submission of the requested information and ...
    (Date:2/28/2017)... -- Medical robots market is projected to reach USD ... 2016, growing at a CAGR of 21.1% in the ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... advancements, increase in funding for medical robots research, issuance ... investments are the key factors driving the growth of ...
    Breaking Medicine Technology:
    (Date:2/28/2017)... CHICAGO, IL (PRWEB) , ... February 28, 2017 , ... ... celebrating ten years of saving lives by empowering young women to live proactively at ... lifetime. 1 in 75 will develop ovarian cancer. Prevention and early detection can save ...
    (Date:2/28/2017)... ... February 28, 2017 , ... February is American Heart Month sponsored by The ... commitment to improving cardiovascular health for themselves, their families and their communities. , ... one in four deaths are caused by heart disease. Nearly half of all Americans ...
    (Date:2/27/2017)... ... ... Bo Chen, PhD is the recipient of the 2017 ASLMS Dr. Horace Furumoto ... at ASLMS 2017, the Annual Conference of the American Society for Laser Medicine & ... , During the Plenary Session on April 7, Dr. Chen will give his award ...
    (Date:2/27/2017)... NEW PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... substance use disorder, but concern for women who become dependent on opioid painkillers has ... 400% among female patients, compared to a 237% increase in fatal overdoses in male ...
    (Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media center ... brings songs, movies, TV shows and much more apps for user exploration. Its innovative ... immersive view of 1280 x 720 provides crisp images with remarkable clarity and color. ...
    Breaking Medicine News(10 mins):